In a significant development for the biotechnology sector, LianBio, a leading player focused on accelerating the differentiation and development of innovative medicines in China and other major Asian markets, has announced an agreement with Janssen Pharmaceutica NV. According to the ground-breaking agreement that hails from Shanghai, China and Princeton, New Jersey, LianBio will be assigning its exclusive rights for an investigational, potential first-in-class radioenhancer, NBTXR3 to Janssen.Janssen, a respected company under the massive Johnson and Johnson umbrella, stands to receive LianBio’s exclusive rights to develop and commercialize NBTXR3 in four major Asian markets. These include China, South Kor...

LIAN's Stock Performance relative to it's Customers

LIAN's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Lianbio	34.19	0.00	-19.50	129
SUBTOTAL	0.00	0.00	0.00	-

Sources: Lianbio’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Lianbio’s corporate clients.
For your research, we’ve provided 9 tables on Lianbio corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.